New drugs at the horizon for men with prostate cancer;Quels nouveaux médicaments à l'horizon pour le traitement du cancer avancé de la prostate?

Revue Medicale Suisse

Volumn 6, Issue 250, 2010, Pages 1057-1061

  Berthold, Dominik R ^a   Shabafrouz, Keyvan ^a   Bauer, Jean ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CALCITRIOL; CETUXIMAB; CILENGITIDE; DASATINIB; DENOSUMAB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MDV 3100; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OGX 011; PACLITAXEL; PACLITAXEL DERIVATIVE; PANOBINOSTAT; PROVENGE; RECEPTOR BLOCKING AGENT; TAK 700; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; DRUG MECHANISM; HUMAN; MALE; METASTASIS; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 77953462032     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
2. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71.
3. * Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
4. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
5. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.
6. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
7. Ryan CJ, Smith MR, Fong L, et al. Phase I Clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8.
8. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95.
9. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501.
10. * Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell 2009;16:458-62.
11. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 2009;27:5011.
12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
13. * Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23:8247-52.
14. Berthold DR, Pond GR, de Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53.
15. Sartor A, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). ASCO-GU Meeting 2010.
16. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
17. Kantoff P, Higano C, Berger E. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). ASCO-GU Meeting 2010.
18. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810-5.
19. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. Urol Oncol 2006;24:250-3.
20. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009;182:2670-5.